Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed a phase 3 trial in skin cancer. Novartis had hoped the COMBI-i ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

The high-stakes nature of cancer care, coupled with rapid scientific advancements, increasing payer and regulatory pressures, ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...